Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome : A study of 103 episodes in 89 adult patients
Copyright © 2017. Published by Elsevier B.V..
OBJECTIVES: Macrophage activation syndrome (MAS) is a life-threatening hyperinflammatory syndrome that can occur during systemic lupus erythematosus (SLE). Data on MAS in adult SLE patients are very limited. The aim of this study is to describe the clinical characteristics, laboratory findings, treatments, and outcomes of a large series of SLE-associated MAS.
METHODS: We conducted a retrospective study that included 103 episodes of MAS in 89 adult patients with SLE.
RESULTS: 103 episodes in 89 adult patients were analyzed. Median age at first MAS episode was 32 (18-80) years. MAS was inaugural in 41 patients (46%).Thirteen patients relapsed. Patients had the following features: fever (100% episodes), increased serum levels of AST (94.7%), LDH (92.3%), CRP (84.5%), ferritin (96%), procalcitonin (41/49 cases). Complications included myocarditis (n=22), acute lung injury (n=15) and seizures (n=11). In 33 episodes, patients required hospitalization in an ICU and 5 died. Thrombocytopenia and high CRP levels were associated independently with an increased risk for ICU admission. High dose steroids alone as first line therapy induced remission in 37/57 cases (65%). Additional medications as first or second line therapies included IV immunoglobulins (n=22), cyclophosphamide (n=23), etoposide (n=11), rituximab (n=3). Etoposide and cyclophosphamide-based regimens had the best efficacy.
CONCLUSION: MAS is a severe complication and is often inaugural. High fever and high levels of AST, LDH, CRP, ferritin and PCT should be considered as red flags for early diagnosis. High dose steroids lead to remission in two third of cases. Cyclophosphamide or etoposide should be considered for uncontrolled/severe forms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Autoimmunity reviews - 16(2017), 7 vom: 23. Juli, Seite 743-749 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gavand, Pierre-Edouard [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 29.11.2017 Date Revised 09.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.autrev.2017.05.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM271688491 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM271688491 | ||
| 003 | DE-627 | ||
| 005 | 20231224233244.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.autrev.2017.05.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0905.xml |
| 035 | |a (DE-627)NLM271688491 | ||
| 035 | |a (NLM)28483541 | ||
| 035 | |a (PII)S1568-9972(17)30130-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gavand, Pierre-Edouard |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome |b A study of 103 episodes in 89 adult patients |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2017 | ||
| 500 | |a Date Revised 09.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017. Published by Elsevier B.V. | ||
| 520 | |a OBJECTIVES: Macrophage activation syndrome (MAS) is a life-threatening hyperinflammatory syndrome that can occur during systemic lupus erythematosus (SLE). Data on MAS in adult SLE patients are very limited. The aim of this study is to describe the clinical characteristics, laboratory findings, treatments, and outcomes of a large series of SLE-associated MAS | ||
| 520 | |a METHODS: We conducted a retrospective study that included 103 episodes of MAS in 89 adult patients with SLE | ||
| 520 | |a RESULTS: 103 episodes in 89 adult patients were analyzed. Median age at first MAS episode was 32 (18-80) years. MAS was inaugural in 41 patients (46%).Thirteen patients relapsed. Patients had the following features: fever (100% episodes), increased serum levels of AST (94.7%), LDH (92.3%), CRP (84.5%), ferritin (96%), procalcitonin (41/49 cases). Complications included myocarditis (n=22), acute lung injury (n=15) and seizures (n=11). In 33 episodes, patients required hospitalization in an ICU and 5 died. Thrombocytopenia and high CRP levels were associated independently with an increased risk for ICU admission. High dose steroids alone as first line therapy induced remission in 37/57 cases (65%). Additional medications as first or second line therapies included IV immunoglobulins (n=22), cyclophosphamide (n=23), etoposide (n=11), rituximab (n=3). Etoposide and cyclophosphamide-based regimens had the best efficacy | ||
| 520 | |a CONCLUSION: MAS is a severe complication and is often inaugural. High fever and high levels of AST, LDH, CRP, ferritin and PCT should be considered as red flags for early diagnosis. High dose steroids lead to remission in two third of cases. Cyclophosphamide or etoposide should be considered for uncontrolled/severe forms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Macrophage activation syndrome | |
| 650 | 4 | |a Systemic lupus erythematosus | |
| 700 | 1 | |a Serio, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Arnaud, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Costedoat-Chalumeau, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Carvelli, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Dossier, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Hinschberger, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Mouthon, Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Le Guern, Véronique |e verfasserin |4 aut | |
| 700 | 1 | |a Korganow, Anne-Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Poindron, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Gourguechon, Clément |e verfasserin |4 aut | |
| 700 | 1 | |a Lavigne, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Maurier, François |e verfasserin |4 aut | |
| 700 | 1 | |a Labro, Guylaine |e verfasserin |4 aut | |
| 700 | 1 | |a Heymonet, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Artifoni, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Viau, Amélie Brabant |e verfasserin |4 aut | |
| 700 | 1 | |a Deligny, Cristophe |e verfasserin |4 aut | |
| 700 | 1 | |a Sene, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Terriou, Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Sibilia, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Mathian, Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Bloch-Queyrat, Coralie |e verfasserin |4 aut | |
| 700 | 1 | |a Larroche, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Amoura, Zahir |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Thierry |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Autoimmunity reviews |d 2002 |g 16(2017), 7 vom: 23. Juli, Seite 743-749 |w (DE-627)NLM126096996 |x 1873-0183 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2017 |g number:7 |g day:23 |g month:07 |g pages:743-749 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.autrev.2017.05.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2017 |e 7 |b 23 |c 07 |h 743-749 | ||